Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 43

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 43
---
 questions about my respective special meeting or the Mergers? |

| A: | If you have questions about your respective special meeting or the Mergers, or desire additional copies of this 
 joint proxy statement/prospectus or additional proxies, you may contact:                                        |

| If you are a TuHURA stockholder:       |     | If you are a Kineta stockholder: |
| TuHURA Biosciences, Inc.               |     | Kineta, Inc.                     |
| 10500 University Center Dr., Suite 110 |     | 7683 SE 27th Street, Suite 481   |
| Tampa, Florida 33612                   |     | Mercer Island, WA 98040          |
| (813) 875-6600                         |     | (206) 378-0400                   |
| Attention: Corporate Secretary         |     | Attention: Corporate Secretary   |

If your shares are held for you by a bank, broker, trust or other nominee, you should also call your bank, broker, trust or other nominee for additional information. 24

SUMMARY

For your convenience, provided below is a brief summary of certain information contained in this joint proxy statement/prospectus. This summary highlights selected information from this joint proxy statement/prospectus and does not contain all the information that may be important to you as a TuHURA or Kineta stockholder. To understand the Mergers fully and for a more complete description of the terms of the Mergers, you should read carefully this entire joint proxy statement/prospectus, its annexes and exhibits and the other documents to which you are referred. Items in this summary include a page reference directing you to a more complete description of those items. A copy of the Merger Agreement is attached as Annex Ato this joint proxy statement/prospectus and is incorporated by reference into this proxy statement/prospectus.

The Parties to the Mergers (see page 174)

TuHURA Biosciences, Inc.

TuHURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome
resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a
single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab